Exercise in a Pill Is Now in Human Trials

Atrogi's ATR-258 just dosed its first subjects — and the muscle data it's hunting could reframe how we treat weight loss.

1

ATR-258 is an oral compound designed to replicate exercise's metabolic effects, including fat loss and muscle preservation.
2

The compound is a GRK2-biased β2-agonist, selectively activating muscle-building signaling without cardiovascular side effects.
3

An 8-week human trial at the University of Copenhagen is focused on muscle physiology data in overweight male volunteers.
4

The study aims to address muscle-sparing weight loss, filling a gap left by current GLP-1 obesity treatments.
5

Results from the trial are expected later this year, with questions remaining about generalizability and long-term outcomes.

1